Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Colorectal Neoplasms 90Carcinoma, Hepatocellular 29Neoplasm Metastasis 18Neoplasms 16Gastrointestinal Stromal Tumors 13Colonic Neoplasms 13Rectal Neoplasms 12Sarcoma 6Glioblastoma 6Stomach Neoplasms 5Sarcoma, Ewing 5Ovarian Neoplasms 5Osteosarcoma 5Melanoma 5Liver Neoplasms 5Cholangiocarcinoma 5Adenocarcinoma 5Pancreatic Neoplasms 4Esophageal Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Small Cell Lung Carcinoma 3Rhabdomyosarcoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Leukemia, Myeloid, Acute 3Colorectal Cancer Metastatic 3Carcinoma, Transitional Cell 3Carcinoma 3Advanced Colorectal Cancer 3Thyroid Neoplasms 2

Interventions

Capecitabine 6Temozolomide 5Octreotide 4Leucovorin 4Everolimus 4Fluorouracil 3Bevacizumab 3vatalanib 2pentetreotide 2Trastuzumab 2Sunitinib 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Cisplatin 2Bortezomib 2Biological Therapy 2veliparib 1tipifarnib 1temsirolimus 1sapanisertib 1romidepsin 1regorafenib 1pazopanib 1palbociclib 1motesanib diphosphate 1lutetium Lu 177 dotatate 1irinotecan sucrosofate 1gallium Ga 68 dotatate 1dehydroftorafur 1cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Somatostatinoma × regorafenib × Clear all
NCT02259725 2021-12-15

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

University of Southern California

Phase 2 Completed
3 enrolled 7 charts
Endocrine

Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡